An investigational antibody-drug conjugate called sacituzumab tirumotecan (sac-TMT) significantly improved overall survival in a global phase 3 trial for patients with heavily pretreated advanced gastroesophageal adenocarcinoma, marking the first time a TROP2-directed ADC has achieved this result in a global study for this cancer type.
How the Treatment Works
Sacituzumab tirumotecan is a TROP2-directed antibody-drug conjugate. It uses an antibody that targets TROP2, a cell-surface protein overexpressed in several solid tumors, including gastroesophageal adenocarcinoma. That antibody is linked to a topoisomerase I inhibitor payload derived from belotecan via a bifunctional linker. The design allows the drug to deliver chemotherapy directly to cancer cells expressing TROP2, aiming to limit damage to healthy tissue.
The agent was discovered by Kelun-Biotech, a China-based biotechnology company. Merck licensed the asset in May 2022, offering up to $1.36 billion in potential milestone payments, and later expanded the collaboration to include seven additional investigational ADCs from Kelun-Biotech for up to $9.3 billion.
TroFuse-015 Trial Design and Survival Data
The phase 3 TroFuse-015 trial (NCT06356311) enrolled 473 patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. All participants had received at least two prior lines of systemic therapy. Patients were randomized to receive sac-TMT at 4 mg/kg on days 1, 15, and 29 of each 6-week cycle, or treatment of physician’s choice (TPC).
The TPC arm consisted of single-agent chemotherapy regimens: trifluridine/tipiracil (Lonsurf) 35 mg/m² orally twice daily on days 1 to 5 and 8 to 12 of a 4-week cycle; irinotecan 150 mg/m² on days 1 and 15 of a 4-week cycle; or paclitaxel 80 mg/m² on days 1, 8, and 15 of a 4-week cycle.
At the final analysis, sac-TMT demonstrated a statistically significant improvement in overall survival, the trial’s primary endpoint. The benefit was consistent across subgroups regardless of tumor TROP2 expression status. However, the trial did not meet its secondary endpoint of progression-free survival (PFS) by blinded independent central review. The objective response rate (ORR) numerically favored sac-TMT but was not formally tested under the prespecified statistical analysis plan.
Safety Profile and Subgroup Findings
Merck reported that the safety profile of sac-TMT in TroFuse-015 was consistent with previous studies and that no new safety signals emerged. Detailed adverse event data from this trial have not yet been released; the company plans to present full results at a future medical meeting.
For context, in the phase 3 TroFuse-005 trial in advanced endometrial cancer — reported in May 2026 and presented at the 2026 ESMO Congress — grade 3 or higher treatment-related adverse events occurred in 54.4% of patients receiving sac-TMT versus 41.4% in the chemotherapy arm. Interstitial lung disease or pneumonitis was reported in 1.8% versus 0.5%, respectively.
Regulatory Path and Future Development
Sac-TMT is currently approved in four indications in China. In the United States, it is under FDA priority review for previously treated endometrial cancer, with a decision expected by June 2027. The asset previously received a Commissioner’s National Priority Voucher, an FDA pilot program launched under former Commissioner Marty Makary that is now reportedly defunct.
Merck intends to discuss the TroFuse-015 data with regulatory authorities and submit the findings for review. The TroFuse program comprises 18 ongoing global phase 3 studies across multiple cancer types, including endometrial, bladder, breast, cervical, gastric, non–small cell lung, and ovarian cancers. Fourteen of those trials are pursuing first-in-class opportunities.
Early findings suggest this agent offers a new mechanism of action for a patient population with limited options. Patients should talk to their doctor or oncologist about what these results may mean for their individual treatment plan.
Sources
- Sacituzumab Tirumotecan Improves OS in 3L+ Gastroesophageal Cancer | Targeted Onc – Immunotherapy, Biomarkers, and Cancer Pathways
- Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
Photo: Bill Branson (Photographer) (Public domain)





